Aptevo Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 8, 2024
APVO$1.13-8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts, unaudited)
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $(3,752) | $(4,168) |
| General and administrative | (3,231) | (3,588) |
| Loss from operations | (6,983) | (7,756) |
| Other income (expense): | ||
| Other income (expense) from continuing operations, net | 149 | (67) |
| Gain related to sale of non-financial asset | — | 9,650 |
| Net (loss) income from continuing operations | $(6,834) | $1,827 |
| Discontinued operations: | ||
| Income from discontinued operations | $— | $946 |
| Net (loss) income | $(6,834) | $2,773 |
| Basic and diluted net (loss) income per share from continuing operations: | ||
| Basic | $(9.95) | $11.45 |
| Diluted | $(9.95) | $11.45 |
| Basic and diluted net (loss) income per share: | ||
| Basic | $(9.95) | $17.38 |
| Diluted | $(9.95) | $17.38 |
| Shares used in calculation: | ||
| Basic | 686,735 | 159,597 |
| Diluted | 686,735 | 159,597 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.